chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient had received covid vaccination and had ambulated over to monitoring area. Complained of dizziness and severe headache. States no history of migraines/headaches or dizziness. Assisted patient to sit down. b/p 161/111 hr 90 sat 98%. 1650 EMS called. 1651 140/76 HR 68 Sat 98% Neuro intact. alert and oriented. States does not take any home medications, no HX HTN. NKDA. 1657 EMS on site. Patient adamant that will not go to hospital. ems waiver form signed. 1657 BP 151/79 HR 70, Sat 98%. Patient denies further dizziness or headache. 15 minute monitoring time was to end at 1651. Patient stated felt better and wanted to go home and left facility.
Two days after getting the vaccine, I had redness and itchiness in my left eye.  The redness and itchiness would subside slightly if I used a cold compress or took Benadryl. The next day, I began to feel lethargic throughout the day.  The lethargy lasted for about 7 days, and the redness and itchiness in my left eye lasted for about 10 days.  All symptoms have subsided.
Breathing was off, it was like it was raspy; Coughing; Chills; Pain throughout my body; This is a spontaneous report from a contactable consumer. This 51-year-old consumer (patient) reported that the patient has received first dose of BNT162B2 (BNT162B2, Solution for injection, Lot number: EW0150, Expiration date: 31Jul2021) through an unspecified route at left arm on 07Apr2021 as a single dose for COVID-19 immunization. The second dose was scheduled on 26Apr2021. The medical history included high blood pressure and asthma; concomitant medication included hydrochlorothiazide (HYDROCHLOROTHIAZIDE). The patient reported that the patient took the shot on Wednesday when patient woke up on Thursday (08Apr2021) morning breathing was off, it was like it was raspy, patient was coughing, had chills, and pain throughout body. The outcome of these events was unknown.  No follow-up attempts are needed. No further information is expected.
Had seizure immediately after getting the shot; This spontaneous case was reported by a consumer and describes the occurrence of SEIZURE (Had seizure immediately after getting the shot) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SEIZURE (Had seizure immediately after getting the shot) (seriousness criterion medically significant). At the time of the report, SEIZURE (Had seizure immediately after getting the shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported. No treatment information was reported. Very limited information regarding the event has been provided at this time. No further information is expected.; Sender's Comments: Very limited information regarding the event has been provided at this time. No further information is expected.
This case was reported by a physician via sales representative and described the occurrence of intussusception in a 2-month-old subject of unspecified gender who was vaccinated with ROTARIX (GlaxoSmithKline). In November 2013 the subject received 1st dose of ROTARIX (1 ml, oral). In November 2013, 6 days after vaccination with ROTARIX, the subject experienced intussusception and GI side effects. The sales representative reported on behalf of the physician that the subject received ROTARIX on an unknown date around 18 or 19 November 2013, exact date was unknown. In November 2013, six days after receiving ROTARIX the subject had GI side effects, (details not provided) and intussusception. The subject was therefore admitted to the hospital (length of stay was unknown) "where some type of colon surgery was performed. As a result of the surgery, the subject is now doing better". The ROTARIX series has likely been discontinued but the reporting sales representative was unsure about this. It was reported that the physician's office reported this occurrence to the CDC. At the time of reporting the intussusception and GI side effects were improved. The subject was hospitalised and the physician considered the events were clinically significant (or requiring intervention). The physician considered the events were probably related to vaccination with ROTARIX.
received his first two doses of GARDASIL 9 in 2019 as scheduled, but never came back for the third dose. He is inquiring about receiving the third dose now; No additional AE/PQC; This spontaneous report as received from a pharmacist regarding a 45-year-old male patient. The patient's concurrent condition, medical history and concomitant medication were not reported.   On unknown dates in 2019, the patient was vaccinated with the first two doses of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (dose, frequency, route of administration, batch/lot# and expiration date were not reported) for prophylaxis as scheduled, but the patient never came back for the third dose (inappropriate schedule of product administration). The patient was inquiring about receiving the third dose now. No additional adverse event reported (no adverse event).
Patient received a booster dose of the Pfizer vaccine when she is outside the approved age group (18+). No symptoms or adverse events are observed currently.
She became diaphoretic, her throat felt dry and as if it was beginning to close. Rapid response was called and she was transported to the ER. She was tachycardic, experienced chest tightness, and shortness of breath.
She had a history of hives and fainting  when she received the pertussis vaccine.  This was her first dose of the COVID-19 vaccine and she had no known allergy to components of the COVID-19 vaccine.  She said she had spoken with her doctor prior to her appointment.  Staff at the vaccination facility set up a precaution in case she fainted including 1:1 observation immediately following injection.  She had no fainting, and proceeded to the post vaccination area after about 15 minutes, when she said she felt fine.  At about 30 minutes after receiving the vaccine, she reported a rash across her chest, visible hives and hot to the touch, and she had a few areas of rash on her arms. She did not express any difficulty breathing. EMS was onsite and were immediately notified.  In the course of her evaluation by EMS, she drank water, used an ice pack on rash, and took her own Benadryl and reported that she was beginning to feel better after approximately 30 more minutes. EMS confirmed that she was stable and okay to leave. On-site DOHMH medical greeter informed her about v-safe, told her to talk with her PCP, and inform people at the time of her next vaccination.  At approximately 6pm, this reporter (non-medical professional) followed up with patient to check on her symptoms. She expressed that she was feeling better, the rash subsided but that her hands were swollen. This reporter reiterated the importance of following up with her regular medical provider.
Within 36 hours of receiving the 2nd dose of vaccine, in addition to the usual side effects of fever, chills, and illness I also developed an adverse reaction which triggered me to have a full-blown episode of Bell's palsy on the entire right side of my body.  This was concentrated particularly on my face and affected my eyelid (opening/shutting), tongue (sense of taste) and included paralysis, loss of sensation, tingling, and numbness.  This lasted for approximately 3 weeks and has not since fully recovered to 100% from before the vaccine.  I do have a history of Bell's palsy but the last time I had an episode was over 15 years ago.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39-year-old male patient received BNT162b2 (BNT162B2), on 25Oct2021 as dose 2 (initial pfizer dose), single (Batch/Lot number: unknown) at the age of 38 years for covid-19 immunisation; janssen coviD-19 vaccine (JANSSEN COVID-19 VACCINE), on 31Mar2021 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "known allergies: penicillin" (unspecified if ongoing);. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid.   Clinical course: Patient received other medications within 2 weeks of vaccination.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
24 h post IZ: generalized body aches, swelling and redness LUA which spread and was itchy. Also  palms red and itchy x 2 D. Used Atarax 10/20 from ER MD 10mg q 6 hrs x 3 with relief.
Upper left arm became sore on or about 5:30 pm April 9.  Roughly 9 days after vaccine.  Became increasingly tender and sore throughout entire day on April 10.  Noticed where injection was given was now a raised bump.  Increasingly itchy and very warm to the touch.  Left arm is increasingly tender and sore to the touch and somewhat throbbing pain down to palms of hands.   After an online search discovered it may be Covid arm.   Tylenol helps ease the pain.   Have also used a Salonpas medicated patch to help with soreness.
This spontaneous report as received from   a pharmacist refers to a 66 year old male patient. No information reported regarding medical history and concurrent conditions. On 15-OCT-2014 the patient was vaccinated with ZOSTAVAX lot # K003597, expire date: 12-MAR-2015, 0.65 ml, subcutaneous (dose number, anatomical locations not reported). No concomitant medications reported. On 17-OCT-2014, (also reported that around 17-OCT-2014 or 18-OCT-2014) the patient experienced yellow raised bump close to injection site after receiving ZOSTAVAX. No treatment was given for adverse event. The patient had visited into the pharmacy on 23-OCT-2014, and sought medical attention. The outcome of yellow raised bump close to injection site was unknown. This is one of two report received from the same reporter. Additional information has been requested.
neck pain; shot up into neck; stomach ache; This spontaneous case was reported by a consumer and describes the occurrence of NECK PAIN (neck pain; shot up into neck) and ABDOMINAL PAIN UPPER (stomach ache) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (not reported).   On 24-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NECK PAIN (neck pain; shot up into neck) and ABDOMINAL PAIN UPPER (stomach ache). At the time of the report, NECK PAIN (neck pain; shot up into neck) and ABDOMINAL PAIN UPPER (stomach ache) outcome was unknown.            This case was linked to MOD-2021-062322 (E2B Linked Report).; Sender's Comments:  MOD-2021-062322:1st dose
4 to 7 mins after receiving covid 19 vaccine patient became dizzy and light headed. Treated with dead breathing, water, and time.  patient started to feel better in aprrox 15 min
After receiving first dose of COVID-19 vaccine series patient began breathing heavily, sweating, and her heart rate became rapid.  She also stated that she was feeling tingling in her extremities and she felt faint.  She was closely monitored by the pharmacist and we attempted to calm her breathing.  While attempting to take her blood pressure she stated that her throat was closing.  She was given epinephrine at 4:11pm and 911 was called.  Upon further evaluation at the ER it was determined that she was experiencing a panic attack.
Information has been received from a physician concerning a 15-year-old male who was vaccinated SC with a 0.5 mL dose of Varivax. The physician reported that the patient subsequently developed breakthrough chickenpox. Unspecified medical attention was sought. At the time of this report, the patient's chicken pox were noted to be improved while on therapy (unspecified). No additional information is expected.
Dizzy; Tender scalp; Achy; Fever; Slightly sore at injection site; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizzy), PAIN OF SKIN (Tender scalp), MYALGIA (Achy), PYREXIA (Fever) and VACCINATION SITE PAIN (Slightly sore at injection site) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037C21A and 004C21A) for COVID-19 vaccination.     No medical history was reported by the reporter.  Concomitant products included ATORVASTATIN and AMLODIPINE for an unknown indication.   On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-May-2021, the patient experienced DIZZINESS (Dizzy), PAIN OF SKIN (Tender scalp), MYALGIA (Achy), PYREXIA (Fever) and VACCINATION SITE PAIN (Slightly sore at injection site). At the time of the report, DIZZINESS (Dizzy), PAIN OF SKIN (Tender scalp), MYALGIA (Achy), PYREXIA (Fever) and VACCINATION SITE PAIN (Slightly sore at injection site) outcome was unknown.            Treatment details was not reported by the reporter.
Patient has a previous history of seizure disorder. She received the vaccination and proceeded to the waiting area. While there she reported to staff embers that she could feel a seizure coming on. She was moved to the floor in a safe location and monitored. She was able to contact her spouse to bring her medication. She began to seize and at one point she did lose consciousness. She regained consciousness and improved rapidly afterwards. EMS was called, but she declined the service. She said that these seizures aren't uncommon and she wanted to go home to recover.
This spontaneous report as received from a registered nurse refers to a 60 year old female patient. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot # not reported). On an unknown date the patient experienced flu symptoms, upper respiratory infection and rash. The outcome of flu symptoms, upper respiratory infection and rash was unknown. The relatedness between the events and ZOSTAVAX was not reported. This is one of several reports received from the same reporter. Additional information has been requested.
Patient did NOT have a reaction.  Patient was given a vaccine that had expired on 03/28/2021
Jynneos vaccine was administrated intradermally; The patient was administered with Jynneos vaccine that was supposed to be discarded after 8 weeks being refrigerated; The patient was administered with Jynneos vaccine that was supposed to be discarded after 8 weeks being refrigerated; Case reference number US-BN-2022-004217 is a spontaneous case report initially received on 20-Oct-2022 from nurse via Communication (reference number: USBAV22-1748) and concerns a patient of unknown gender and age.  The patient's medical history and concomitant medication details were not provided.  On 19-Oct-2022, the patient was vaccinated with the first dose of Jynneos vaccine (Smallpox and Monkeypox Vaccine, Live, Nonreplicating; batch number: FDP00002), at a dose reported as 0.1 mL, administered intradermally (explicitly coded as 'Intradermal injection') at unknown site of administration, indicated for Monkeypox Prophylaxis.  As reported, the patient was administered with Jynneos vaccine that was supposed to be discarded after 8 weeks being refrigerated (explicitly coded as 'Expired vaccine used' and 'Product storage error').  At the time of this report, it was unknown if the patient experienced any adverse event.  Additional information received on 20-Oct-2022 from included the local ID number.; Reporter's Comments: A patient of unknown age or gender was vaccinated with the first dose of Jynneos vaccine on 19-Oct-22. The vaccine was administered intradermally, at a dose reported as 0.1ml for monkeypox prophylaxis which is coded as intradermal injection. Reportedly, the patient was administered with Jynneos vaccine that was supposed to be discarded after 8 weeks being refrigerated which is considered expired vaccine used and product storage error. All events are listed per the Company conventions. The patient's medical history and concomitant medications were unknown. It was unknown if the patient experienced any adverse events following vaccination. Intradermal injection, expired vaccine used and product storage error are assessed as not related to the suspect vaccine, but related to a human factor. The case is non-serious.; Sender's Comments: A patient of unknown age or gender was vaccinated with the first dose of Jynneos vaccine on 19-Oct-22. The vaccine was administered intradermally, at a dose reported as 0.1ml for monkeypox prophylaxis which is coded as intradermal injection. Reportedly, the patient was administered with Jynneos vaccine that was supposed to be discarded after 8 weeks being refrigerated which is considered expired vaccine used and product storage error. All events are listed per the Company conventions. The patient's medical history and concomitant medications were unknown. It was unknown if the patient experienced any adverse events following vaccination. Intradermal injection, expired vaccine used and product storage error are assessed as not related to the suspect vaccine, but related to a human factor. The case is non-serious.
I suddenly felt very lightheaded and weak. I thru up and passed out. Then I went to sleep. It happened again a couple of weeks later, and I went to the ER room. The doctors have not found out any correlating event that would make sense yet. I was told to follow up with a cardiologist, I haven't done this yet. I am not sure if this is from the shot or not.
Leg swelling started evening of vaccine, worsened into next day.  feels warm at site and red.
Pain severe enough to affect my movements such as from chairs and bed; had a significant increase in muscular and joint related pain in the time since my second vaccination; had a significant increase in muscular and joint related pain in the time since my second vaccination; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Pain severe enough to affect my movements such as from chairs and bed), MYALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination) and ARTHRALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN (Pain severe enough to affect my movements such as from chairs and bed), MYALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination) and ARTHRALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination). At the time of the report, PAIN (Pain severe enough to affect my movements such as from chairs and bed), MYALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination) and ARTHRALGIA (had a significant increase in muscular and joint related pain in the time since my second vaccination) outcome was unknown.            No concomitant product use was provided by the reporter.   No treatment medications were reported.
DTaP and Hep A vaccines administered to the patient on the morning of may 5, 2008. The next morning ,on may 6, 2008, the patient's left thigh was swollen. The child's mother took him to the pediatrician who diagnosed cellulitis and ordered Augmentin P.O. No redness or heat was observed in the left thigh.
Redness & swelling at shot site warm to the touch. Treated w/KEFLEX 250mg/5ml 2 tsp PO three times per day x 10 days.
Approximately 10-15 minutes following vaccination, patient complained of tingling in right hand and diaphoresis ("fire feeling all over"). Pt was evaluated by physician and nurse at vaccine center. At ~7:32pm, tingling resolved, still felt warm but better. Vitals stable throughout. Observed for a total of 30 mins- d/c to home. F/up made to pt the following day- no concerns offered.
shortness of breath, chest discomfort/pain, exceptioally tired, cough, low fever
Initial report received from a health care professional on 06 May 2010: This adolescent was vaccinated with MENVEO (batch number: 027011, 090901), (dose: unknown) intramuscularly on 30 Apr 2010. The patient was administered MENVEO that was not reconstituted before administration and the lyophilized portion was not administered. No adverse event had occurred.
Rash at injection site 8 days post-vaccination. Rash has spread to cover the length of the left arm, chest, and torso.
This spontaneous report as received from a Certified Medical Assistant (C.M.A.) via a company representative refers to an 11 year old male patient. On an unknown date the patient was vaccinated with the first dose of GARDASIL (lot # not reported) intramuscularly in the left arm. Concomitant therapies included ADACEL and MENACTRA which were vaccinated on the right arm on the same day. The patient experienced patient's left arm swelled up at the injection site shortly after GARDASIL was vaccinated. Patient sought medical attention by office visit and not treatment was given to patient. The outcome of patient's left arm swelled up at the injection site was unknown. Additional information has been requested.
Resident reported feeling unusual and fuzzy/Frequent Urination. Resident started antibiotic for Urinary Track Infection
sore jaw; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN JAW (sore jaw) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN JAW (sore jaw). At the time of the report, PAIN IN JAW (sore jaw) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Immediately, post vax, I experienced extreme pain at the site with diaphoresis and pain down my whole left arm. This subsided in about 5 minutes. The next day, I developed right cervical lymphadenopathy (painful) and fatigue. The local erythema and large nodule with tenderness to palpation, improved (redness about 5 days). The nodule still present after 20 days. Fatigue lasted 10 days, LAD (R) lasted about 5 days and then had left cervical LAD X 1-2 days. Had 1st JEV vaccine on 6/6/00; SC/RA.